Novavax is one of the more unusual setups in biotech right now — a stock that has rallied 38% in a month while carrying one of the heaviest short positions in the sector, with borrowing conditions tightening sharply just as the price pushes higher.
The short position here is genuinely large. Short interest runs at roughly 27.7% of free float, with around 45 million shares sold short. That number has barely moved over the past week — down just 0.1% — meaning covering activity has not been the driver of the rally. Over the past month, short interest actually crept up about 2.4%. The cohort betting against NVAX is staying put despite a stock that has climbed from below $8 to $10.12. What makes the borrow picture more interesting is the recent tightening in availability. Availability has dropped to just 11.3% — meaning for every share already borrowed, less than one-eighth of that number remains available to lend. That is a marked deterioration from the 39.6% reading a week ago, and sits well below the mid-month levels of 48%. The 52-week low availability touched 0.15%, so there is room to tighten further, but the direction is clear. Cost to borrow, by contrast, remains low at under 1%, so the mechanics of shorting are not expensive yet — just increasingly constrained on supply. Options traders have turned more defensive in tandem. The put/call ratio reached 0.616, nearly two standard deviations above its 20-day mean of 0.54. That is the most hedged reading in weeks, and it has been climbing since late August even as the stock gained ground — a divergence worth noting.
The Street is split, and the gap between targets reflects genuine uncertainty about NVAX's commercial path. The mean analyst price target is around $14, implying roughly 38% upside from current levels — a significant premium that has not closed despite the recent rally. Bulls point to Novavax's Matrix-M adjuvant technology and its Sanofi partnership as durable differentiators. Nuvaxovid's tolerability profile versus mRNA alternatives remains the core commercial argument. Bears counter that COVID vaccine market share is structurally declining and that differentiation on tolerability may not be enough in an increasingly crowded field. The most recent analyst action — BTIG reiterating a Buy with a $19 target in June — is broadly in line with the bullish camp, though TD Cowen held at Hold with a $9 target in May, bracketing the stock's current price almost perfectly. Factor scores add a nuanced layer: EPS momentum ranks in the 95th percentile over 30 days and 94th over 90 days, suggesting the earnings revision trend is firmly positive. But the short score of 81 places NVAX in the top 2% of the most shorted universe, and days-to-cover ranks in the bottom 7th percentile — a combination that historically defines a high-friction name.
The activist register adds another layer to an already complex setup. Himanshu H. Shah of Shah Capital Management holds a Schedule 13D position — an activist filing, not a passive one — at approximately 9% of the company, as last disclosed in May. Shah Capital is the largest single holder in the institutional register, just ahead of BlackRock at 8.5% and State Street at 7.1%. The 13D designation matters: it signals active intent rather than index-tracking exposure, and the position has been built across four filings since October 2025. As always with 13D/G disclosures, stakes reflect the last-reported position around the 5% threshold and may have changed since filing. Notably, D.E. Shaw trimmed its position by over 2 million shares and Millennium Management cut by roughly 2 million as well — both quantitative funds reducing exposure even as the activist held steady.
NVAX's peer group spent the week in reverse. EDIT fell 6.4% over the period, CRBU dropped nearly 12%, and BEAM lost 6.5%. Novavax's 7.2% weekly gain stands in stark contrast to every correlated name in its cluster — none of which posted positive weekly returns. That divergence raises the question of whether NVAX is responding to company-specific news flow or whether a covering dynamic is beginning, however quietly, to develop beneath the surface.
With the next earnings event scheduled for November 9, the next major data point is some weeks away. The tension to watch is whether the tightening availability begins to feed into borrow costs — and whether that combination, alongside an 81-point short score and a 28% short float, shifts the arithmetic for the cohort still holding positions against a stock that has gained 38% in a month.
See the live data behind this article on ORTEX.
Open NVAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
